A sputum 6-gene signature predicts airway inflammation endotypes and exacerbation frequency in chronic obstructive pulmonary disease.
Thomas SouthworthZala JevnikarChristopher McCraeDave SinghPublished in: Biomarkers in medicine (2022)
Aim: To validate a sputum 6-gene signature (6GS), comprising of CLC , CPA , DNASE1L3 , IL-1B , ALPL and CXCR2 , for identifying different endotypes in chronic obstructive pulmonary disease. Methodology & results: Sputum cell CLC , CPA3 and DNASE1L3 gene expression correlated with eosinophil percentage, while IL-1B , ALPL and CXCR2 correlated with neutrophil percentage. Hierarchical cluster analyses of IL-1B , ALPL and CXCR2 , and CLC , CPA3 and DNASE1L3 , identified patient groups that differed in their sputum neutrophil and eosinophil levels, respectively. Multiple logistic regressions demonstrated that the 6GS could distinguish between eosinophil High and eosinophil Low patients, as well as neutrophil High and neutrophil Low , and could also predict exacerbation history. Conclusion: The 6GS may have applications in clinical practice or for stratifying patients for clinical trials.
Keyphrases
- end stage renal disease
- cystic fibrosis
- gene expression
- mycobacterium tuberculosis
- clinical trial
- pulmonary tuberculosis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- chronic obstructive pulmonary disease
- clinical practice
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- genome wide
- stem cells
- dna methylation
- copy number
- single cell
- case report
- bone marrow
- intensive care unit
- open label